IDEAYA Biosciences, Inc. (IDYA), a clinical-stage oncology company, announced the pricing of an underwritten public offering of 5.56 million shares at an offering price of $27.00 per share and pre-funded warrants to purchase up to 5.56 million shares at an offering price of $26.9999 per pre-funded warrant. The aggregate gross proceeds to IDEAYA are expected to be approximately $300.0 million.
In addition, IDEAYA has granted the underwriters a 30-day option to purchase up to an additional 1.67 million shares of its common stock at the public offering price per share.
The offering is expected to close on or about June 10, 2026, subject to customary closing conditions.
J.P. Morgan, Jefferies, TD Cowen, UBS Investment Bank, and Cantor are acting as joint book-running managers for the offering.
IDEAYA's lead investigational candidate is Darovasertib, an oral, selective protein kinase C inhibitor which is being evaluated to treat uveal melanoma, ocular cancer.
IDYA has traded between $20.50 and $39.28 over the last year. The stock closed Monday's trade at $31.48, up 11.28%.
In the overnight market, IDYA is down 4.83% to $29.96.
For More Such Biotech Stock News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.